7 minutes | Thursday, August 20, 2026
A new personalized vaccine, called Intismeran, was given in combination with Keytruda, an immunotherapy drug already used in cancer treatment, stopped skin cancer returning in patients during a trial, representing a potentially watershed moment in cancer treatment. The vaccine, developed by drug companies Merck & Co and Moderna, was given to patients with high-risk melanoma, a type of skin cancer, after they had surgery. The two companies are testing other similar personalized vaccines for lung, bladder, and kidney cancers.